Persistence Market Research Blog

Posts tagged ‘Biological Drugs’

Global Biological Drugs Market to Reach US$287139.7 Million by 2020 owing to Rising Incidence of Chronic Diseases

New York City, New York, Oct 14, 2015: According to the latest market research report released by Persistence Market Research, the global biological drugs market, which in 2014 stood at US$161056.5 million is anticipated to expand at a CAGR of 10.1% between 2014 and 2020, thereby reaching a market value of US$287139.7 million by 2020. The report titled “Global Market Study on Biological Drugs: North America to Witness Highest Growth By 2020” is available for sale on the company website.

Request Sample Report: (more…)


Global Biological Drugs Market: North America to Witness Highest Growth by 2020

Biological drugs are typically derived from living cells and are used in treatment of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders. Biological drugs have more complex structure than conventional drugs. These are highly sensitive and more difficult to characterize and produce. A biological drug typically has around 250 in-process tests during manufacturing compared to about 50 tests for a conventional drug.

The global market of biological drugs is categorized based on therapeutic protein, mAb and vaccines. The therapeutic protein segmentation is further sub-segmented into Enbrel, Lantus, Neulasta, Avonex, NovoLog, Rebif, Humalog, Aranesp, Epogen, Levemir, Victoza, Betaseron, Neupogen, and Eylea.  The mAb segment comprises Humira, Remicade, Rituxan, Avastin, Herceptin and Lucentis. The vaccine segment is further sub-segmented into Prevnar 13, Gardasil, Fluzone, Varivax and Cervarix.

In terms of geography, North America has the largest market share followed by Europe and Asia in the global biological drugs market. Increased usage of biological drugs for the treatment of diseases, such as cancer, diabetes and other chronic diseases, are supporting the growth of the biological drugs market in the North American region. For instance, in 2012, the American College of Rheumatology, an organization that advances rheumatology through education and research, recommended biologic agents and disease modifying antirheumatic drugs for the treatment of rheumatoid arthritis.

Read complete report at

Tag Cloud